Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zogenix's long-acting hydrocodone meets chronic pain endpoint, ready for 2012 filing

This article was originally published in Scrip

Executive Summary

Zogenix said that its Zohydro product, an extended-release capsule formulation of hydrocodone bitartrate without acetaminophen (paracetamol), met the primary endpoint vs placebo in a pivotal Phase III trial to treat chronic pain, paving the way for regulatory review by the US FDA in early 2012.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC014112

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel